Chronic myeloid leukaemia (CML) is primarily treated using imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting the BCR::ABL1 oncoprotein. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.